Summary: New research indicates that a class of HIV medications known as nucleoside reverse transcriptase inhibitors (NRTIs) may substantially lower the risk of developing Alzheimer’s disease. By analyzing two large U.S. health databases, investigators found that patients taking NRTIs experienced an annual reduction in Alzheimer’s risk of roughly 6% to 13%.
Unlike many other antiretroviral drugs, NRTIs also inhibit inflammasomes—immune system complexes implicated in neuroinflammation and the progression of Alzheimer’s disease. The research team recommends clinical trials to evaluate NRTIs and a newer, potentially safer inflammasome-blocking compound called K9 for Alzheimer’s prevention as global case numbers continue to rise.
Key facts:
- Risk reduction: NRTI exposure was associated with a 6% to 13% annual decrease in the risk of developing Alzheimer’s disease in two separate datasets.
- Drug specificity: The protective association was seen with NRTIs specifically; other classes of HIV medications did not show the same link.
- Next steps: Authors call for randomized clinical trials of NRTIs and the novel inflammasome inhibitor K9 to assess their potential for preventing Alzheimer’s disease.
Source: University of Virginia
UVA Health researchers say clinical trials are needed to test whether certain HIV drugs can prevent Alzheimer’s disease after finding substantially lower rates of the condition among patients on these medications.
The study was led by Jayakrishna Ambati, MD, founding director of UVA’s Center for Advanced Vision Science and the DuPont Guerry III Professor in the School of Medicine’s Department of Ophthalmology. His team had previously identified a mechanism by which NRTIs may block inflammasome activation, a pathway linked to neurodegeneration.
To test whether patients on inflammasome-blocking NRTIs had lower dementia rates, the researchers examined two comprehensive health databases: 24 years of records from the U.S. Veterans Health Administration and 14 years of data from the MarketScan database of commercially insured patients. The combined analysis included more than 270,000 individuals aged 50 or older who were prescribed medications for HIV or hepatitis B (both conditions treated with NRTIs) and who did not have a prior Alzheimer’s diagnosis.
Across the two datasets, patients taking NRTIs showed a statistically significant and clinically meaningful reduction in the subsequent development of Alzheimer’s disease. After accounting for potential confounding factors—such as age, existing medical conditions, and other medications—the association remained robust: one dataset showed an approximate 6% annual reduction in risk, and the other showed about a 13% annual reduction.
Importantly, the investigators found that other types of antiretroviral drugs did not demonstrate the same protective signal, strengthening the hypothesis that the inflammasome-inhibiting action of NRTIs may be the key factor. Based on these retrospective findings, the research team urges prospective clinical trials to determine whether NRTIs or next-generation inflammasome inhibitors can safely and effectively prevent Alzheimer’s disease.
If validated in randomized trials, repurposing NRTIs or deploying newer agents like K9 could have far-reaching public health implications. Alzheimer’s prevalence is rising: nearly 7 million Americans currently live with the disease, with projections reaching 13 million by 2050. The economic burden is also substantial, with annual care costs in the hundreds of billions of dollars—figures expected to grow if preventative strategies are not discovered.
Ambati and colleagues also reported the development of K9, a novel inflammasome-blocking compound described as a potentially safer and more targeted successor to NRTIs. K9 is already being evaluated in clinical trials for other inflammatory conditions, and the team plans to explore its application in Alzheimer’s disease pending further study.
Findings published
The full analysis appears in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The author team includes Joseph Magagnoli, Meenakshi Ambati, Tammy Cummings, Joseph Nguyen, Claire C. Thomas, Vidya L. Ambati, S. Scott Sutton, Bradley D. Gelfand and Jayakrishna Ambati. Jayakrishna Ambati is also listed as a co-founder of several related companies; disclosures are detailed in the published paper.
Funding: This research was supported by the UVA Strategic Investment Fund, the National Institutes of Health (multiple grants), the DuPont Guerry III Professorship, and private support from Mr. and Mrs. Eli W. Tullis.
About this neuropharmacology and Alzheimer’s disease research news
Author: Josh Barney
Source: University of Virginia
Contact: Josh Barney – University of Virginia
Image: Image credited to Neuroscience News
Original Research: The findings are published in Alzheimer’s & Dementia